GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Valuation Rank

NeuroPace (NeuroPace) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is NeuroPace Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NeuroPace Valuation Rank Related Terms

Thank you for viewing the detailed overview of NeuroPace's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroPace (NeuroPace) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Valuation Rank
Comparable Companies
ZIMV OM BFLY SMLR MASS ALUR AXGN XTNT TELA CLPT ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
Website
https://www.neuropace.com
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Executives
Martha Morrell officer: Chief Medical officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd. 10 percent owner CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker director, officer: Chief Executive Officer ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley officer: General Counsel and Secretary C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade director 6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield director C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer director 9701 JERONIMO, IRVINE CA 92618
Evan Norton director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob director 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet director, officer: Chief Executive Officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043